Compare · NVS vs RARE
NVS vs RARE
Side-by-side comparison of Novartis AG (NVS) and Ultragenyx Pharmaceutical Inc. (RARE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVS and RARE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $284.62B, about 131.9x RARE ($2.16B).
- RARE has hit the wire 11 times in the past 4 weeks while NVS has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- Novartis AG
- Ultragenyx Pharmaceutical Inc.
- Price
- -
- -
- Market cap
- $284.62B
- $2.16B
- 1M return
- -
- -17.37%
- 1Y return
- -
- -41.67%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 0
- 11
- Recent ratings
- 25
- 25
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders. The company is also developing DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
- Citigroup initiated coverage on Novartis AG
Latest RARE
- Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
- Chief Financial Officer Horn Howard sold $110,602 worth of shares (4,653 units at $23.77), decreasing direct ownership by 4% to 105,689 units (SEC Form 4)
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Director Fust Matthew K was granted 7,751 shares, increasing direct ownership by 30% to 33,696 units (SEC Form 4)
- Director Suliman Shehnaaz was granted 7,751 shares and sold $144,189 worth of shares (5,740 units at $25.12), increasing direct ownership by 8% to 27,951 units (SEC Form 4)
- Director Ray Amrit was granted 7,751 shares, increasing direct ownership by 33% to 31,116 units (SEC Form 4)
- Director Sanders Corazon (Corsee) D. was granted 7,751 shares, increasing direct ownership by 51% to 23,095 units (SEC Form 4)
- Director Narachi Michael was granted 7,751 shares, increasing direct ownership by 24% to 40,441 units (SEC Form 4)
- Director Welch Daniel G was granted 7,751 shares, increasing direct ownership by 24% to 40,441 units (SEC Form 4)
- Director Dunsire Deborah was granted 7,751 shares, increasing direct ownership by 25% to 38,566 units (SEC Form 4)